774-P: Not Carbohydrate but Sucrose Intake Is Associated with Gut Dysbiosis in Japanese Patients with Type 2 Diabetes

Abstract

Background: There is a close association between gut dysbiosis and type 2 diabetes (T2D). However, little is known about gut dysbiosis in Japanese patients with T2D and the association between gut dysbiosis and habitual dietary intake is also unknown. Methods: In this cross-sectional study, 97 patients with T2D and 97 subjects without T2D matched by age and sex were selected. We obtained 16S rRNA metagenomic data from fecal samples. Habitual dietary intake of patients with T2D was evaluated by brief-type self-administered diet history questionnaire. Paired t test was used for the difference between patients with T2D and subjects without T2D. Spearman’s rank correlation coefficient was used for association between gut dysbiosis and habitual dietary intake. Results: At the phylum level, the abundance of Actinobacteria or Firmicutes in patients with T2D was higher than that in subjects without T2D, whereas that of Bacteroidetes or Fusobacteria in patients with T2D was lower (Figure). Sucrose intake was associated with the abundance of Actinobacteria (r=0.29, p<0.01) or that of Bacteroidetes (r=-0.29, p<0.01), whereas carbohydrate intake was not (r=0.03, p=0.77 or r=-0.12, p=0.25, respectively). Conclusion: The abundance of gut microbiota differs between patients with T2D and subjects without, and not carbohydrate but sucrose intake is associated with gut dysbiosis in Japanese patients with T2D. Disclosure Y. Hashimoto: Research Support; Self; Asahi Kasei Pharma. M. Hamaguchi: None. A. Kaji: None. R. Sakai: None. R. Inoue: None. S. Kashiwagi: None. K. Mizushima: None. K. Uchiyama: None. T. Takagi: None. Y. Naito: None. M. Fukui: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Johnson & Johnson, Kyowa Hakko Kirin Co., Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sanwa Kagaku Kenkyusho, Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; AstraZeneca, Eli Lilly and Company, Kowa Pharmaceutical Europe Co. Ltd., Kyowa Hakko Kirin Co., Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sanwa Kagaku Kenkyusho, Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited. Funding Japan Society for the Promotion of Science (16675576 to Y.N.); Ministry of Agriculture, Forestry and Fisheries of Japan (16824414 to Y.N.)